Olivier Rascol And NotEspagne

List of bibliographic references

Number of relevant bibliographic references: 15.

Ident.	Authors (with country if any)	Title
000689	Clive Ballard [Royaume-Uni] ; Stuart Isaacson [États-Unis] ; Roger Mills [États-Unis] ; Hilde Williams [États-Unis] ; Anne Corbett [Royaume-Uni] ; Bruce Coate [États-Unis] ; Rajesh Pahwa [États-Unis] ; Olivier Rascol [France] ; David J. Burn [Royaume-Uni]	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
000871	Olivier Rascol [France] ; Susan Fox [Canada] ; Fabrizio Gasparini [Suisse] ; Christopher Kenney [États-Unis] ; Thérèse Di Paolo [Canada] ; Baltazar Gomez-Mancilla [Canada]	Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
000B86	Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France]	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
000F08	Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Kathryn A. Chung [États-Unis] ; Robert A. Hauser [États-Unis] ; Janis M. Miyasaki [Canada] ; Anthony P. Nicholas [États-Unis] ; Werner Poewe [Autriche] ; Klaus Seppi [Autriche] ; Olivier Rascol [France] ; Mark A. Stacy [États-Unis] ; John G. Nutt [États-Unis] ; Caroline M. Tanner [États-Unis] ; Alison Urkowitz [États-Unis] ; Jean A. Jaglin [États-Unis] ; Song Ge [États-Unis]	Which dyskinesia scale best detects treatment response?
000F10	Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France]	Trial designs used to study neuroprotective therapy in Parkinson's disease
001474	Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Nègre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarié [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France]	A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease
001786	Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]	The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
001787	Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]	The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
001813	Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]	Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
001826	Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche]	Milestones in Parkinson's disease therapeutics
001C40	Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas]	Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
002525	Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]	Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
002852	Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]	Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
002E27	Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
003336	Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France]	Dopamine agonists: Their role in the management of Parkinson's disease

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022